glp 1 and gip receptor agonist Potential Use of GLP-1 GIP/GLP-1 Agonists for Respiratory Disorders: Where Are We at? Potential Use of GLP-1 and

The development of dual GIPRGLP1R coagonists that bind to either one or the other receptor (sequence-mixed dual agonists) has emerged as an innovative therapeutic strategy for obesity and type 2 diabetes

Rationale Obesity remains a major global health challenge, severely affecting metabolic and cardiovascular health

Coverage of GLP-1 weight-loss drugs is growing among the largest employers (5000+ workers), now at 43%

A comprehensive phase 3 program is ongoing to evaluate efficacy, safety, and cardiovascular/renal outcomes in people with obesity and/or T2D

Intention-to-treat analyses resulted in an HR of 1.36 (95% CI 0.51, 3.61)

Molecular Formula: CHNO